Rafferty Asset Management, LLC Revance Therapeutics, Inc. Transaction History
Rafferty Asset Management, LLC
- $26.7 Billion
- Q1 2024
A detailed history of Rafferty Asset Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 17,325 shares of RVNC stock, worth $44,525. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,325
Previous 28,580
39.38%
Holding current value
$44,525
Previous $251,000
66.14%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding RVNC
# of Institutions
214Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$13.9 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...